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INSOMNIA IS A PREVALENT AND DISTRESSING ISSUE 
FOR BREAST CANCER PATIENTS.1-6 HOWEVER, THE 
PROCESS OF INSOMNIA IN THIS POPULATION HAS 
been largely understudied. Knowledge of this process would 
not only aid in further understanding insomnia in the context 
of breast cancer, but it would also foster the development of 
insomnia interventions for this population so that this prevalent 
and distressing issue could be better managed.
One model commonly used to understand the process of in-
somnia is a cognitive-behavioral model, which asserts that both 
dysfunctional sleep related thoughts (e.g., worries about the 
consequences of insomnia) and behaviors (e.g., napping, ex-
tending the opportunity to sleep, staying in bed awake) perpetu-
ate insomnia long after precipitating factors may dissipate.7,8 A 
large body of research shows support for this model in the con-
text of primary insomnia (i.e., insomnia without any comorbid 
condition)9-13 and demonstrates the efficacy and effectiveness of 
cognitive-behavioral therapy for insomnia (CBT) for primary 
insomnia.14 In addition, a few studies have shown support for 
aspects of this model in the context of insomnia comorbid with 
breast cancer3,15-19 as well as demonstrated the efficacy of CBT 
for this population.20-22
Although a cognitive-behavioral model of insomnia shows 
promise in understanding the process of insomnia in breast 
cancer patients, cancer-related factors that could potentially 
contribute to sleep difficulties must be considered. Breast can-
cer symptoms, such as pain, fatigue, hot flashes, and mood 
disturbance, are of particular interest as these symptoms have 
been shown to be associated with poorer sleep in this popu-
lation.2,3,19,23-27 Therefore, the current study sought to examine 
the contribution of pain, fatigue, hot flashes, mood disturbance, 
dysfunctional sleep related thoughts, and sleep inhibitory be-
haviors to the process of insomnia in breast cancer patients.
Process-related questions are challenging to answer with 
traditional statistical techniques, which typically treat data in 
a cross-sectional and aggregated fashion. Fortunately, there is 
a methodological approach, which has been used in other areas 
(e.g., pain and mood) to examine process-related questions.28,29 
This approach is called a daily process approach, which in-
cludes repeated prospective measurement of variables that are 
considered to change in meaningful ways on a daily basis.30 Us-
ing sophisticated multilevel modeling techniques, this approach 
provides the unique opportunity to examine relationships as 
they occur over time.30-33 For example, one can examine wheth-
er higher levels of pain during the day are related to poorer 
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sleep that night and/or if poorer sleep that night is related to 
higher levels of pain the next day.
Therefore, using a daily process approach, the current study 
addressed three main questions in a population of breast cancer 
patients with insomnia. First, to examine nighttime associations, 
what is the day-to-day relationship between sleep and nighttime 
pain and hot flashes? Second, to examine the antecedents of 
poorer sleep, what is the day-to-day relationship between day-
time symptoms, dysfunctional sleep related thoughts, and sleep 
inhibitory behaviors and that night’s sleep? Third, to examine 
the consequences of poorer sleep, what is the day-to-day rela-
tionship between sleep and the next day’s symptoms, dysfunc-
tional sleep related thoughts, and sleep inhibitory behaviors?
METHODS
Design and Procedure
The current study used a within-group longitudinal research 
design. All study procedures were reviewed and approved by the 
Duke University Medical Center Institutional Review Board. Pro-
spective participants were provided a full explanation of the study. 
Consenting participants then completed screening procedures, in-
cluding structured diagnostic interviews for sleep and psychiatric 
disorders and a measure of insomnia severity. All screening proce-
dures were conducted by an advanced doctoral student in clinical 
psychology with supervision from a licensed clinical psychologist 
with 25 years of experience with sleep disordered patients.
After completing the screening procedures, eligible partici-
pants underwent a 28-day diary phase in which they completed 
a morning diary before 12:00 and an evening diary after 18:00 
using an automated telephone-based data collection system 
(VoiceGuide, Katalina Technologies, Sydney, Australia), which 
provided a time and date stamp for each entry. Participants were 
compensated $0.15 for each diary completed at the appropriate 
date and time, and $1.65 for a full week of diaries completed 
on time for a possible total of $15.00 for all diaries. In addi-
tion, participants were called weekly (4 phone calls total) dur-
ing the diary phase and given feedback about diary completion 
as well as an opportunity to ask any questions. Participants also 
recorded their medication use daily during the diary phase us-
ing a paper medication log. These logs were then mailed back 
at the end of the diary phase.
Participants
Five hundred seven breast cancer patients (stages I-IIIa) who 
had completed their primary cancer treatment (i.e., surgery, che-
motherapy, and/or radiation) at Duke University Medical Center 
were sent recruitment letters for the current study. Of these po-
tential participants, a number either did not respond to the recruit-
ment letter (n = 193), had no sleep difficulties (n = 164), or lacked 
interest in participating (n = 64). Of the remaining potential par-
ticipants (n = 86), 44 patients with insomnia were enrolled in the 
current study. The other 42 patients were excluded and not en-
rolled in the study as they: (a) had another uncontrolled medical 
condition (e.g., arthritis, thyroid disease) compromising sleep (n 
= 9); (b) met Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition, (DSM-IV) criteria for a current mood, anxi-
ety, alcohol or substance abuse, or psychotic disorder on the basis 
of the Structured Clinical Interview for DSM-IV Axis I Disorders 
(SCID-I)34 (n = 11); (c) met criteria for another current sleep dis-
order (e.g., sleep apnea, restless leg syndrome) as assessed by the 
Duke Structured Interview for Sleep Disorders (DSISD)35 (n = 
16); or (d) had other significant issues impacting their sleep (e.g., 
caregiving) or their ability to participate (e.g., cognitive difficul-
ties) (n = 6). These exclusion criteria were included so that the 
study sample had only sleep difficulties related to insomnia and 
cancer and was able to complete the study.
The 44 participants enrolled in the study met research di-
agnostic criteria (RDC)36 for primary insomnia or insomnia 
comorbid with cancer as assessed by the DSISD.35 Of the 44 
patients enrolled, 2 patients completed less than 50% of the dia-
ries and 1 patient withdrew shortly after enrollment, so these 3 
participants consequently were not included in the final sample 
of the current study. The mean age for the final sample (N = 
41) was 57 years (SD = 8.22), and the sample was mostly Cau-
casian (97.6%). Approximately 75.6% had received at least a 
college degree, 75.6% were married, and 58.5% were working.
In terms of breast cancer diagnosis, participants had been 
diagnosed with breast cancer for an average of 5.85 years (SD 
= 3.65); 34.15% had stage I breast cancer, 53.66% had stage 
II breast cancer, and 12.20% had stage IIIa breast cancer. In 
addition, 2 participants had a second primary breast cancer 
(stage 0 and II). All patients had completed their primary treat-
ment (i.e., surgery, chemotherapy, and/or radiation). In terms 
of past primary treatment, 46.34% received lumpectomy, 
53.66% received mastectomy, 68.29% received chemotherapy, 
and 70.73% received radiation. In terms of hormone therapy 
(e.g., tamoxifen), 90.24% received past hormone therapy, and 
68.29% of the sample was receiving hormone therapy at the 
time of the current study. A little over half the sample (56.10%) 
was pre- or peri-menopausal prior to breast cancer treatment, 
and 100% of the sample was either peri- or post-menopausal 
after breast cancer treatment completion.37
In terms of insomnia diagnosis, 29 participants met criteria 
for primary insomnia, and 12 met criteria for insomnia comor-
bid with breast cancer. The average insomnia duration was 7.74 
years (SD = 8.06), and 30 participants reported sleep difficulties 
starting after their breast cancer diagnosis, whereas 11 reported 
aggravation of pre-existing sleep difficulties with their breast 
cancer diagnosis. In addition, the sample scored an average of 
11.88 (SD = 3.58) on the Insomnia Severity Index (ISI). An 
optimal clinical cutoff score of 8 has been recommended for 
cancer patients,38 and 90.24% of the sample scored at or above 
this clinic cutoff. A small portion of the sample (n = 4) scored 
below this cut-off as there were no frequency or severity inclu-
sion/exclusion criteria for this study.
Daily Measures
Morning daily diaries
Participants completed diaries every morning before 12:00 
during the diary phase using an automated telephone-based 
data collection system. The morning diaries assessed sleep, 
pain, and hot flashes the previous night, and dysfunctional 
sleep related thoughts and sleep inhibitory behaviors the pre-
vious day and night.
Sleep diaries are a valid index of insomnia in that they pro-
vide the best indication of patient perception of sleep difficulties 
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and are more accurate than a one-time retrospective sleep esti-
mate.39 As recommended by Buysse et al.,40 sleep was assessed 
daily by having participants log estimates of the time they went 
to bed (e.g., 22:30), the time they attempted to fall asleep (e.g., 
23:00), how long it took them to fall asleep (e.g., 90 min), the 
number and duration of nocturnal awakenings (e.g., 2 awaken-
ings lasting 20 and 60 min each), the time of their last awaken-
ing (e.g., 05:30), the time they got out of the bed (e.g., 07:00), 
and their overall sleep quality on a scale ranging from 0 (very 
poor) to 9 (excellent). From these data, only 2 sleep variables 
were extracted as a proxy for insomnia with the aim of limiting 
the number of statistical analyses. Sleep efficiency [(total sleep 
time)/(time in bed) * 100] was selected as it captures both sleep 
duration and time in bed, and sleep quality was selected as it 
captures the participant’s overall impression of sleep.
One item assessed the level of pain the previous night on 
a scale from 0 (no pain) to 9 (pain as bad as you can imag-
ine). This item (“How much pain did you have last night?”) 
was adapted from the Brief Pain Inventory (BPI), which is a 
measure that is commonly used with cancer patients to assess 
pain.41 Items from this measure have demonstrated excellent 
test-retest reliability (r ranging from 0.78 to 0.93).42 The va-
lidity of the BPI has also been supported by studies that have 
shown a significant relationship between higher pain ratings 
and increased analgesic and narcotic use.42
One item assessed the severity of hot flashes the previous 
night on a scale from 0 (not at all severe) to 9 (extremely severe). 
This item (“How severe were your hot flashes last night?”) was 
selected from a questionnaire developed by Carpenter et al.24,43 
The hot flash severity item has demonstrated validity in that this 
item has been shown to be significantly related to items on the 
Hot Flash Daily Interference scale, which measures the overall 
impact of hot flashes on quality of life (r ranging from 0.57 to 
0.78), and these significant relationships were maintained when 
hot flash severity and daily interference items were assessed 6 
months later in this same sample (r ranging from 0.48 to 0.76).43
The Glasgow Sleep Effort Scale (GSES) assessed dysfunc-
tional sleep related thoughts.44 This scale was developed to assess 
sleep effort and can be used as a proxy for concerns about sleep. 
For the current study, this scale was adapted to reflect on thoughts 
the previous day and night versus over the past week with items 
such as “I got anxious about sleeping before I went to bed last 
night.” and “I worried about not sleeping when I was in bed last 
night and could not sleep.” Participants indicated how much they 
agree with each statement by indicating not at all, to some ex-
tent, or very much. Evidence supports the reliability of this scale 
(Cronbach α = 0.77).44 Kohn and Espie45 also found that this scale 
best discriminated individuals with insomnia from those without 
sleep complaints compared to other similar scales. This scale has 
also demonstrated excellent sensitivity and specificity, in that a 
cut-off score of 2 correctly identified 92.1% of individuals with 
insomnia and 87.3% of individuals without sleep complaints.44
Nine items from the Sleep Hygiene Practice Scale (SHPS) 
were used to assess sleep inhibitory behaviors.11 These 9 items 
(e.g., “I took a nap yesterday.” and “I set aside time to relax 
before bedtime last night.”) were selected based on the most 
frequently endorsed items from a pilot study conducted in our 
lab that investigated sleep inhibitory behaviors in breast cancer 
patients with insomnia.19 Six of these 9 items assessed sleep in-
hibitory behaviors (i.e., napping, using sleep medication, drink-
ing caffeinated beverages within 4 h of bedtime, exercising 
strenuously within 2 h of bedtime, sleep disturbance by noise, 
and sleep disturbance by a bed partner), and 3 items assessed 
sleep promoting behaviors (i.e., setting aside time to relax be-
fore bedtime, exercising in the afternoon or early evening, and 
having a comfortable nighttime temperature in the bedroom). 
Participants indicated whether they engaged in each activity or 
had each experience (i.e., “yes” or “no”). To score this measure, 
the sleep promoting behaviors were reverse scored, and then all 
items were summed. The SHPS has demonstrated good test-re-
test reliability (r = 0.74).46 This measure also has demonstrated 
good evidence of validity in that insomnia sufferers who report 
higher levels of sleep inhibitory behaviors show significantly 
poorer sleep quality, and that this measure discriminates pa-
tients meeting criteria for insomnia from those who do not.11,45,46
Evening daily diaries
Participants completed diaries every evening after 18:00 dur-
ing the diary phase using an automated telephone-based data 
collection system. The evening diary assessed pain, fatigue, hot 
flashes, and mood during that day. The same items used in the 
morning diary to assess pain and hot flashes during the night 
were used in the evening diary to assess pain and hot flashes 
during the day (“How much pain did you have today?” and 
“How severe were your hot flashes today?).
One item assessed the level of fatigue during the day on a 
scale from 0 (no fatigue) to 9 (fatigue as bad as you can imag-
ine). This item (“How fatigued have you been today?”) was 
adapted from the Brief Fatigue Inventory (BFI), which is a 
measure that is commonly used with cancer patients to assess 
fatigue.47 Items from this measure have demonstrated criterion 
validity in that they have correlated highly with other well-vali-
dated fatigue measures (r ranging from 0.59 to 0.68).48
A mood rating scale assessed mood disturbance.49 This scale 
consists of 5 negative affect items (e.g., “How depressed/blue 
have you felt today?”) and 4 positive affect items (e.g., “How 
happy have you felt today?”). On a scale ranging from 0 (not at 
all) to 6 (extremely much), participants rated the degree to which 
they experienced each mood. Negative and positive affect items 
were averaged into 2 scales, negative mood and positive mood, 
respectively. Higher scores on either scale indicate higher levels 
of that particular mood. This measure has demonstrated excellent 
reliability in a sample of patients with sickle cell disease (Cron-
bach α = 0.88 for positive mood and 0.89 for negative mood).50 In 
addition, this measure was developed for daily use and has been 
used in daily diary studies with various populations, including 
patients with breast cancer as well as college students.49,51
Medication use
Using paper medication logs, participants were asked to report 
the type and dose of the medications they took the previous day 
each morning during the diary phase. Participants then mailed 
back these paper logs at the end of the diary phase. Each partici-
pant’s medication use was quantified using the Medication Quan-
tification Scale, Version 3 (MQS-III).52 The MQS was developed 
within persistent pain populations and quantifies medication use 
by employing a common scale based on a mixture of assigned 
detriment weights for various pharmacological classifications of 
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were completed on time. Forty participants (97.6%) also com-
pleted a medication log daily during the 28-day diary phase. 
These figures were only slightly lower when examining the 
compliance data from the 2408 diaries requested from all en-
rolled participants who started the diary phase (N = 43). That 
is, 2209 (91.7%) entries were completed, 2116 (87.9%) were 
completed on time, and 40 participants (93.0%) completed a 
28-day medication log.
Descriptive Findings and Between-Person Relations
For the purposes of preliminary analysis, mean scores were 
calculated for each of the daily diary measures across the 28-
day period for each participant. A mean score was also cal-
culated for medication use using the MQS-III score. Table 1 
presents the means, standard deviations, and ranges for these 
results. On average, participants slept approximately 6.5 h, 
had a sleep efficiency indicating that the slept about 82% of 
the time they spent in bed, and rated their sleep quality in the 
mid-range of this scale. These sleep characteristics are similar 
to median values from Espie et al.’s sample21 of cancer survi-
vors with insomnia. All values for pain, hot flashes, fatigue, 
negative mood, and positive mood were similar to other pub-
lished diary study samples of breast cancer survivors.24,51,58 On 
average during the day and night, participants endorsed low 
levels of dysfunctional sleep related thoughts and approxi-
mately 2 sleep inhibitory behaviors. As these scales have not 
been used in diary studies with cancer patients, we are uncer-
tain if these values are similar to other published breast can-
cer survivor samples. Finally, although clinical categories are 
not available for the medication measure, the current sample’s 
medication use is higher than a previously published sample 
of individuals with persistent pain and insomnia who had a 
score of 5.1 (SD = 6.4).57
For the purposes of preliminary analysis, the data were in-
spected for potentially important covariates (i.e., a number of 
demographic, medical, and insomnia variables). Demographic 
variables included age, level of education, marital status, and 
working status. Medical variables included the number of years 
since diagnosis, stage of breast cancer, lumpectomy, mastecto-
my, chemotherapy, radiation, past or current hormone therapy, 
current hormone therapy, current medication use, and change 
in menopausal status. Insomnia variables included insomnia di-
agnosis (primary insomnia or insomnia comorbid with breast 
cancer), insomnia duration, and insomnia symptom severity. 
Using correlational analyses, results revealed no significant re-
lationships between any of the above potential covariates and 
both sets of aggregated diary variables (sleep as well as symp-
toms, dysfunctional sleep related thoughts, and sleep inhibitory 
behaviors). Race was not included in these variables, as the cur-
rent sample was predominantly Caucasian. Thus, no covariates 
were identified for the remaining analyses.
Approach to Multilevel Analysis
The remaining analyses derive from a class of statistical 
procedures called random effects multilevel modeling.30,32,33 
These procedures partition the 2 sources of variance in our 
person-day dataset—differences between persons in the aver-
age levels of the daily variables and differences within persons 
in their daily reports over time. In the vernacular of multilevel 
medications and dosage levels. The scores for each medication 
are then summed to yield the total MQS score for each participant 
with higher scores indicating higher levels of medication use.
The MQS-III accounts for the following pharmacological 
classifications of medications: acetaminophen, anticonvulsants, 
antihypertensives, barbiturates, benzodiazepines, coclooxygen-
ase-2 inhibitors, muscle relaxants, nonsteroidal anti-inflamma-
tories, opioids, psychotropics, sedative hypnotics, and steroids.52 
In prior studies, the MQS has demonstrated excellent interrater 
reliability (r ranging from 0.95 to 0.99).53,54 These studies have 
also demonstrated concurrent validity of this scale in that the 
higher scores on the MQS have been shown to significantly re-
late to higher levels of pain severity and interference.53,54
Baseline Measure
Insomnia Severity Index
The Insomnia Severity Index (ISI)55 was given prior to the 
diary phase during the screening phase and assessed the per-
ceived severity of insomnia over the course of the previous 
two weeks. The ISI consists of the following 7 items rated by 
participants on a 5-point scale from 0 to 4: the degree of dif-
ficulty falling asleep, staying asleep, and waking up too early 
as well as the degree of dissatisfaction with their sleep patterns, 
how noticeable their sleep difficulties are to others, and their 
distress/worry about their sleep difficulties. These items were 
then summed to make a score ranging from 0 to 28 with higher 
scores indicating greater insomnia severity. The ISI has recently 
demonstrated excellent reliability and validity in various cancer 
populations.38 The ISI has also demonstrated excellent reliabil-
ity and validity in the general population.56
RESULTS
Daily Diary and Medication Log Compliance
Of the 2296 diaries requested from the final sample (N = 
41), 2128 (92.7%) entries were completed, and 2052 (89.4%) 
Table 1—Means, standard deviations, and ranges of aggregated daily 




Total sleep time (in minutes) 399.50 45.42 270.7–496.9
Sleep efficiency (%) 81.93 7.04 62.9–92.9
Sleep quality 5.09 1.04 3.0–8.2
Nighttime pain 1.55 1.28 0.0–5.1
Nighttime hot flashes 1.95 1.72 0.0–6.1
Daytime pain 1.57 1.18 0.0–4.4
Daytime fatigue 3.33 1.27 1.1–5.5
Daytime hot flashes 2.01 1.71 0.0–6.1
Daytime negative mood 0.78 0.64 0.0–2.8
Daytime positive mood 3.78 0.73 2.6–5.0
Daytime/nighttime dysfunctional 
sleep related thoughts 1.49 1.21 0.1–4.7
Daytime/nighttime sleep inhibitory 
behaviors 1.89 0.74 0.4–3.3
Medication use 7.56 7.23 0–25
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Table 3 displays the results, which revealed that less efficient 
sleep and poorer sleep quality were significantly related to both 
increased nighttime pain and hot flashes.
Lagged Within-Person Relations: Daytime Symptoms, 
Dysfunctional Sleep Related Thoughts, and Sleep Inhibitory 
Behaviors Predicting That Night’s Sleep
For the second set of analyses, a series of regression equa-
tions examined the within-person relations of daytime symp-
toms, dysfunctional sleep related thoughts, and sleep inhibitory 
behaviors predicting that night’s sleep (e.g., how does pain 
experienced during the day relate to less efficient sleep that 
night?). Each regression equation also controlled for the previ-
ous night’s sleep variable (i.e., sleep efficiency or sleep quality) 
to better assess temporality in these associations. That is, ex-
amining the change in tonight’s sleep compared to the previous 
night’s sleep that may be due to that day’s symptoms, dysfunc-
tional sleep related thoughts, and sleep inhibitory behaviors. To 
illustrate these models, the equation of that day’s pain predict-
ing that night’s sleep efficiency was as follows:
(that night’s sleep efficiency)it = b0 +b1 (that day’s paint) +
b2 (the previous night’s sleep efficiencyt) + et
Table 4 displays these results, which revealed that higher 
levels of dysfunctional sleep related thoughts and sleep inhibi-
tory behaviors for the previous day and night were significantly 
related to less efficient sleep and poorer sleep quality that night. 
modeling, level 1 units refer to the dis-
crete reports of sleep, pain, fatigue, hot 
flashes, negative mood, positive mood, 
dysfunctional sleep related thoughts, and 
sleep inhibitory behaviors. In the current 
study, multilevel analyses addressed the 
within-person relations between level 1 
variables over time. More specifically, 
these analyses examined one set of same-
day within-person relationships (i.e., the 
relationship between sleep and nighttime 
pain and hot flashes) and 2 sets of lagged 
within-person relationships (i.e., how dai-
ly symptoms, dysfunctional sleep related 
thoughts, and sleep inhibitory behaviors 
predict that night’s sleep as well as how 
sleep predicts the next day’s symptoms, 
dysfunctional sleep related thoughts, and 
sleep inhibitory behaviors) to address the 
study questions.
The SAS Proc Mixed procedure for 
multilevel data analysis furnished param-
eters in the form of unstandardized maximum likelihood esti-
mates (SAS Institute, 1996). In these analyses, all predictors 
were person-centered, and intercepts and slopes were allowed 
to vary randomly; this enabled us to generalize the findings to 
the population of persons from which the sample was drawn, to 
the population of observations from which their daily reports 
were sampled, and to the population of within-person relations 
in which these samples are intended to represent.30 The covari-
ance matrix was unstructured, allowing different variances for 
the slope, intercept, and the slope-variance correlation. Due to 
the exploratory nature of this study, α was set at the 0.05 level 
for all analyses.
Between- and Within-Person Variability in Daily Diary Measures
The total variance in daily measures across the diary period 
is composed of differences between persons in their average 
scores (i.e., the trait component of the daily diary measures) 
and differences within persons in the fluctuation of these scores 
(i.e., the state component of these measures). Table 2 lists the 
between- and within-person variance components, their signifi-
cance, and the relative contribution of each component to the 
total variance of scores. Results revealed that there is sufficient 
between- and within-person variation to warrant further multi-
level modeling analyses for all variables.33
Same-Day Within-Person Relations: Sleep with Nighttime Pain 
and Hot Flashes
For the first set of analyses, a series of regression equations 
examined the within-person relations of sleep with nighttime 
pain and hot flashes (e.g., how does less efficient sleep at night 
relate to that night’s pain?). Each regression equation fit the 
error terms to a first-order autoregressive model, AR(1), to 
control for autocorrelation. To illustrate these models, the 
equation relating nightly sleep efficiency to nighttime pain 
was as follows:
(nightly pain)it = b0 +b1 (nightly sleep efficiencyt) + et
Table 2—Components of variance for daily diary measures










Sleep efficiency 43.39* 27.7 113.33* 72.3
Sleep quality 0.91* 20.7 3.49* 79.3
Nighttime pain 1.53* 49.8 1.54* 50.2
Nighttime hot flashes 2.83* 68.0 1.33* 32.0
Daytime pain 1.30* 48.9 1.36* 51.1
Daytime fatigue 1.49* 39.5 2.28* 60.5
Daytime hot flashes 2.81* 68.4 1.30* 31.6
Daytime negative mood 0.38* 37.3 0.64* 62.7
Daytime positive mood 0.38* 37.6 0.63* 62.4
Daytime/nighttime dysfunctional 
sleep related thoughts 1.30* 27.8 3.37* 72.2
Daytime/nighttime sleep 
inhibitory behaviors 0.50* 36.8 0.86* 63.2
*P < 0.0001
Table 3—Unstandardized maximum likelihood estimates (b) for within-
person relations between sleep and nighttime pain and hot flashes
Nighttime Pain Nighttime Hot Flashes
Sleep Variable b t P b t P
Sleep Efficiency -0.01 -3.77 0.0002 -0.02 -3.79 0.0002
Sleep Quality -0.11 -3.44 0.0006 -0.17 -4.49  < 0.0001
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Results revealed that poorer sleep 
was significantly related to higher 
levels of nighttime pain and hot 
flashes. Past cross-sectional research 
has demonstrated a relationship of 
poorer sleep to pain and hot flashes in 
breast cancer patients.2,3,24,27 What is 
novel about the findings of the pres-
ent study is that they were obtained 
using a daily process approach. Tak-
en together, these collective findings 
suggest that there is a clear relation-
ship of poorer sleep to pain and hot 
flashes in breast cancer patients.
The second research question 
examined potential antecedents of 
daily insomnia in breast cancer pa-
tients (What is the day-to-day re-
lationship between daytime symptoms, dysfunctional sleep 
related thoughts, and sleep inhibitory behaviors and that night’s 
sleep?). Analyses of these lagged effects revealed that dysfunc-
tional sleep related thoughts and sleep inhibitory behaviors for 
the previous day and night consistently and significantly pre-
dicted less efficient sleep and poorer sleep quality that night. 
The finding that both dysfunctional sleep related thoughts and 
sleep inhibitory behaviors were antecedents of poor sleep fits 
well with a cognitive-behavioral model of insomnia, which as-
serts that insomnia is perpetuated by both maladaptive cogni-
tions and behaviors.7,8 These findings also correspond well with 
those of our pilot study, which found that breast cancer patients 
with insomnia had significantly higher levels of dysfunctional 
sleep related thoughts and a variety of sleep inhibitory behav-
iors than breast cancer patients without sleep complaints.19
Past cross-sectional research has demonstrated a relation-
ship of sleep to pain, fatigue, hot flashes, and mood distur-
bance.2,3,19,23-27 However, it is important to note that the results 
from the current study using a daily process approach found 
that these other potential antecedents (e.g., daytime pain, fa-
tigue, hot flashes, positive mood, and negative mood) did not 
predict poorer sleep that night.
The third and final research question examined potential 
consequences of daily insomnia in breast cancer patients (What 
is the day-to-day relationship between sleep and the next day’s 
symptoms, dysfunctional sleep related thoughts, and sleep in-
hibitory behaviors?). In terms of sleep predicting the next day’s 
symptoms, results revealed that poorer sleep significantly pre-
dicted higher levels of pain, fatigue, and hot flashes, and lower 
levels of positive mood the next day. Prior cross-sectional stud-
ies have reported a relationship of sleep to pain, fatigue, hot 
flashes, and mood in breast cancer patients.2,3,19,23,24,26,27 These 
cross-sectional studies, however, did not have the ability to ex-
amine the direction of relationships between sleep and these 
symptoms. However, the current study, which used lagged anal-
yses, suggests that poorer sleep can lead to an array of symp-
tom-related consequences.
This study also examined whether or not a poorer night’s 
sleep predicted the next day’s dysfunctional sleep related 
thoughts and behaviors. Surprisingly, this study only found that 
lower levels of sleep quality during the night predicted signifi-
On the other hand, daytime symptoms were not found to signifi-
cantly relate to a change in that night’s sleep.
Lagged Within-Person Relations: Sleep Predicting the Next 
Day’s Symptoms, Dysfunctional Sleep Related Thoughts, and 
Sleep Inhibitory Behaviors
For the third set of analyses, a series of regression equations 
examined the within-person relations of sleep predicting the 
next day’s symptoms, dysfunctional sleep related thoughts, and 
sleep inhibitory behaviors (e.g., how does less efficient sleep 
at night relate to the next day’s pain?). Each separate regres-
sion equation controlled for the previous day’s daytime variable 
(pain, fatigue, hot flashes, negative mood, positive mood, sleep 
related thoughts, or sleep related behaviors) to better assess 
temporality in these associations. That is, examining the change 
in today’s symptoms, thoughts, and behaviors compared to the 
previous day’s symptoms, thoughts, and behaviors that may be 
due to the previous night’s sleep. To illustrate these models, 
the equation of that night’s sleep efficiency predicting the next 
day’s pain was as follows:
(the next day’s pain)it = b0 +b1 (that night’s sleep efficiencyt) +
b2 (the previous day’s paint) + et
Tables 5 and 6 display the results from this set of analyses. 
Results revealed that poorer sleep quality was significantly re-
lated to increased pain, fatigue, and hot flashes the next day. 
Results also revealed that less efficient sleep was significantly 
related to increased fatigue and hot flashes the next day. In 
terms of mood, results revealed that less efficient sleep was 
significantly related to lower levels of positive mood the next 
day. In terms of dysfunctional sleep related thoughts, results 
revealed that poorer sleep quality was significantly related to 
lower levels of dysfunctional sleep related thoughts the next 
day. Sleep did not significantly predict changes in sleep inhibi-
tory behaviors the next day.
DISCUSSION
Using a daily process approach, the current study addressed 
three main questions. The first research question examined the 
relationship between sleep and nighttime pain and hot flashes. 
Table 4—Unstandardized maximum likelihood estimates (b) for the within-person relations of daytime 
symptoms, dysfunctional sleep related thoughts, and sleep inhibitory behaviors predicting that night’s sleep
That Night’s Sleep Efficiencya That Night’s Sleep Qualityb
Daytime Variables b t P b t P
Daytime pain  0.09  0.26 0.7922 -0.09 -1.52 0.1291
Daytime fatigue  0.24  0.91 0.3650 -0.03 -0.44 0.6591
Daytime hot flashes -0.44 -1.29 0.1988  0.04  0.60 0.5484
Daytime negative mood -0.47 - 0.79 0.4291 -0.03 -0.34 0.7326
Daytime positive mood  0.34  0.68 0.4974  0.05  0.54 0.5922
Daytime/nighttime dysfunctional 
sleep related thoughts -4.17 -6.48  < 0.0001 -0.74 -8.64  < 0.0001
Daytime/nighttime sleep 
inhibitory behaviors -1.68 -3.53 0.0004 -0.29 -3.50 0.0005
acontrolling for the previous day’s sleep efficiency; bcontrolling for the previous day’s sleep quality
SLEEP, Vol. 33, No. 11, 2010 1507 Factors Contributing to Insomnia in Breast Cancer Survivors—Rumble et al
hensive model includes not only dysfunctional sleep related 
thoughts and behaviors, but also the cancer-related symptoms 
of fatigue, pain, hot flashes, and mood disturbance. More spe-
cifically, in terms of nighttime associations, higher levels of 
both pain and hot flashes were associated with higher levels 
of sleep difficulties. In addition, lagged associations identified 
higher levels of dysfunctional sleep related thoughts and be-
haviors as antecedents of insomnia and higher levels of pain, 
fatigue, hot flashes, and lower levels of positive mood as con-
sequences of insomnia. Thus, given the antecedent findings, 
a comprehensive insomnia intervention for this population 
could use a traditional insomnia-focused CBT protocol as its 
foundation. Given the nighttime association findings, a com-
prehensive insomnia intervention also needs to incorporate 
new intervention components that address nighttime pain and 
hot flashes.
Future research could expand upon these findings by test-
ing the efficacy of a more comprehensive insomnia interven-
tion for this population in improving not only sleep, but also 
pain, fatigue, hot flashes, and positive mood. Future research 
also could expand upon these findings by examining how the 
relationships of interest differ among participants with distinc-
tive characteristics (e.g., patients closer to time of diagnosis 
versus those further from diagnosis). Finally, future research 
could examine the process of insomnia with similar methods in 
other insomnia populations (e.g., insomnia comorbid with psy-
chiatric illness, primary insomnia) as this study only examined 
the insomnia process in middle-aged breast cancer survivors.
cantly lower levels of dysfunctional sleep related 
thoughts the next day. This result does not fit well 
with a cognitive-behavioral model of insomnia, 
which asserts that both dysfunctional sleep re-
lated thoughts and sleep inhibitory behaviors 
perpetuate insomnia. One possible explanation 
for these findings relates to the way in which the 
data were collected for both dysfunctional sleep 
related thoughts and behaviors. The simplest 
approach would have been to collect measures 
of thoughts and behaviors at the end of the day 
when collecting other daytime measures (day-
time pain, fatigue, hot flashes, negative mood, 
and positive mood). However, in the current 
study, the scales assessing thoughts and behav-
iors contained items assessing these factors dur-
ing the day, at bedtime, and throughout the night. 
Given the nature of these measures, they were 
collected in the morning along with measures of 
sleep and nighttime pain and hot flashes. Thus, 
this methodological choice may account for the 
unexpected findings.
This study has several strengths. First, the cur-
rent study utilized a daily process approach and 
sophisticated multilevel modeling techniques to 
examine the day-to-day within-person relation-
ships among sleep, cognitive-behavioral factors, 
and breast cancer-related symptoms. The knowl-
edge of these relationships is important not only 
because it enables one to develop a more com-
prehensive model of insomnia in breast cancer 
patients, but also because it can inform the development of fu-
ture insomnia interventions for breast cancer patients. Second, 
the present study used an automated telephone-based data col-
lection system to collect diary data. This data collection system 
provided a time and date stamp for all entries so that diary com-
pliance could be assessed. Finally, the current study employed 
standardized diagnostic interviews to determine if patients met 
eligibility/ineligibility criteria in terms of sleep and psychiatric 
disorders, which insures greater reliability of the study sample’s 
characterization overall. Taken together, these strengths are 
noteworthy refinements over prior research.
This study also has several limitations. One limitation al-
ready noted is the possible methodological issue with how the 
data were collected for dysfunctional sleep related thoughts and 
behaviors. Future studies should develop more comprehensive 
measures for both thoughts and behaviors that could be admin-
istered both before bedtime and in the morning. Another limi-
tation is the lack of racial diversity in the study sample. Thus, 
future studies need to replicate these findings with more racially 
diverse samples. Finally, although participants underwent struc-
tured diagnostic interviews for sleep and psychiatric disorders, 
participants did not undergo polysomnography or other medi-
cal assessments to further rule out other comorbidities. Future 
studies should incorporate these additional screening features 
to further insure the sample’s characteristics.
In conclusion, the current study found support for a com-
prehensive cognitive-behavioral model of insomnia for breast 
cancer patients using a daily process approach. This compre-
Table 5—Unstandardized maximum likelihood estimates (b) for the within-person relations of 





















































acontrolling for the previous day’s pain; bcontrolling for the previous day’s fatigue; ccontrolling 
for the previous day’s hot flashes; dcontrolling for the previous day’s negative mood; 
econtrolling for the previous day’s positive mood
Table 6—Unstandardized maximum likelihood estimates (b) for the within-person relations 
of sleep predicting the next day’s dysfunctional sleep related thoughts and sleep inhibitory 
behaviors
Dysfunctional Sleep Related Thoughtsa Sleep Inhibitory Behaviorsb
Sleep Efficiency Sleep Quality Sleep Efficiency Sleep Quality
b t P b t P b t P b t P
0.01 1.31 0.19 0.11 2.45 0.01 -0.001 -0.48 0.63 0.01 0.55 0.58
acontrolling for the previous day’s dysfunctional sleep related thoughts; bcontrolling for the 
previous day’s sleep inhibitory behaviors
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